Report of Foreign Issuer (6-k)
01 July 2019 - 9:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
July 2019
Commission File Number:
0001723069
Tiziana Life Sciences plc
(Exact Name of Registrant as Specified in Its
Charter)
3
rd
Floor,
11-12 St James’s Square
London SW1Y 4LB
United Kingdom
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
o
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On July 1, 2019, Tiziana Life Sciences plc
(the “
Company
”) issued a regulatory news service announcement, announcing the publication of an Independent
Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays
in progression of Type 1 Diabetes (the “
RNS Announcement
”).
The RNS Announcement is furnished herewith
as Exhibit
99.1
to this Report on Form 6-K. The information in the attached Exhibit
99.1
is being furnished and shall not
be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject
to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the
Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be
expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
TIZIANA LIFE SCIENCES PLC
|
|
|
|
|
Date: July 1, 2019
|
By:
|
/s/ Kunwar Shailubhai
|
|
|
Name:
|
Kunwar Shailubhai
|
|
|
Title:
|
Chief Executive Officer
|
EXHIBIT INDEX
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jul 2023 to Jul 2024